Advanced Training in Urologic Oncology

描述(申请人提供)：泌尿系癌症给美国人的健康带来了巨大的负担。2012年，估计将有5.8万人死于由泌尿外科医生治疗的癌症，这一数字占所有癌症死亡率的近10%。考虑到泌尿系癌症影响老年人的普遍倾向，这些数字预计只会在未来几十年随着美国总人口的老龄化而上升。与此同时，癌症领域的转化科学和卫生服务研究的创新和发现步伐继续加快。这些综合因素需要一支准备充分的面向研究的工作队伍，能够提出和回答与临床相关的科学问题，这些问题有可能转化为有影响力的发现。值得注意的是，一些消息来源表明，今天只有一小部分泌尿外科医生拥有这种技能。这个T32应用程序的主要目标是根据学员的兴趣，通过提供包括翻译实验室科学或卫生服务研究方面的指导培训选项的综合培训计划，为泌尿外科学员的学术生涯做好准备。该项目的调查主题将基于密歇根大学综合癌症中心21名多学科外部资助教职员工的研究重点和专业知识，这些教职员工来自密歇根大学医学院的泌尿系、内科、放射肿瘤学、病理学、外科、人类遗传学和药理学系，以及密歇根大学公共卫生学院和密歇根大学牙学院的教职员工。这项提议是一项新的申请，每年轮流培训1-2名研究员，为期2年。泌尿系统肿瘤学培训计划(UOTP)的主要目标是为个人在学术泌尿系统肿瘤学领域的研究和教学生涯做好准备。拥有医学博士学位或医学博士学位的泌尿外科毕业实习医生。学位将符合条件。UOTP是围绕导师监督的研究项目和必要的核心课程构建的，该核心课程由可能获得硕士学位的特定研究生水平课程组成。接受培训后，每位学员将在以下两种途径中选择一种：转化性实验室科学或卫生服务研究。该计划的目标是确保每个受训人员：1)设计、实施、分析和报告研究项目，2)获得基本研究方法的正式指导，3)获得癌症生物学基本原理(翻译科学轨道)或进行卫生服务研究的基本要素(卫生服务轨道)的指导。将特别强调阐述和测试解决临床重要问题的假设。将向所有受训人员提供有效传播科学成果和准备赠款方面的额外培训。UOTP的最终目标是为学术泌尿系统肿瘤学的独立职业培训人员做准备。

DESCRIPTION (provided by applicant): Urologic cancers impose a significant burden on the health of Americans. In 2012, an estimated 58,000 individuals will die from cancers that fall under an urologist's care, a figure that accounts for close to 10% of all cancer mortality. Given the general propensity for urologic cancers to affect older people, these numbers are only expected to rise over the next several decades as the overall population of the United States ages. At the same time, the pace of innovation and discovery in translational science and health services research in the area of cancer continues to accelerate. These combined factors require a well prepared research oriented work force that is capable of asking and answering clinically relevant scientific questions that have potential to be translated into impactful discoveries. Notably, a number of sources suggest that today, only a small fraction of urologic surgeons possess such skills. The primary goal of this T32 application is to prepare urology trainees for an academic career in urologic oncology by providing a comprehensive training program comprised of mentored training options in either translational laboratory science or health services research, based upon trainee interest. Investigative themes of the program will be based on the research focus and expertise of a group of 21 multi-disciplinary externally funded faculty members in the University of Michigan Comprehensive Cancer Center composed of individuals from the Departments of Urology, Internal Medicine, Radiation Oncology, Pathology, Surgery, Human Genetics, and Pharmacology- all in the University of Michigan Medical School as well as faculty from the University of Michigan School of Public Health and the University of Michigan School of Dentistry. This proposal is a new application to train 1-2 fellows per year, on an alternate basis, for 2 years. The major objective of the Urologic Oncology Training Program (UOTP) is to prepare individuals for research and teaching careers in the field of academic Urologic Oncology. Graduating urology residents having an M.D. or M.D./PhD. degree will be eligible. The UOTP is structured around a research project supervised by the mentor and a required core curriculum comprised of specific graduate level courses that may lead to a Masters degree. Following acceptance, each trainee will choose between 1 of 2 tracks: translational laboratory science or health services research. The goals of the program are to ensure that each trainee: 1) design, implement, analyze and report a research project, 2) obtain formal instruction on fundamental research methods and 3) gain instruction on either fundamental principles of cancer biology (translational science track) or essential elements of conducting health services research (health services track). There will be a special emphasis on formulating and testing hypotheses that address clinically important questions. Additional training in the effective communication of scientific results as well as grant preparation will be provided to all trainees. The ultimate goal of the UOTP is to prepare trainees for independent careers in academic urologic oncology.